Zuellig Pharma
Concise Prescribing Info
Etelcalcetide HCl
Secondary hyperparathyroidism (SHPT) in adult patients w/ chronic kidney disease (CKD) on haemodialysis therapy.
Dosage/Direction for Use
Initially 5 mg 3 times/wk by bolus inj. Titrate so that doses are individualised between 2.5 & 15 mg. Dose may be increased in 2.5 or 5 mg increments no more frequently than every 4 wk to a max of 15 mg 3 times/wk.
Hypersensitivity. Do not initiate if corrected serum Ca is less than the lower limit of the normal range.
Special Precautions
Risk of hypocalcaemia; adynamic bone in patients w/ PTH levels <100 pg/mL. Measure serum Ca levels prior to treatment, w/in 1 wk of initiation or dose adjustment & every 4 wk during treatment. Ventricular arrhythmia & QT prolongation secondary to hypocalcaemia. Patients w/ history of convulsion disorder or CHF. Monitor for positive binding Abs in SHPT patients treated w/ Parsabiv for up to 6 mth. Co-administration w/ drugs lowering serum Ca. Certain potential manifestations of hypocalcaemia may affect ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Decreased blood Ca; nausea, vomiting, diarrhoea; muscle spasms. Hypocalcaemia, hyperkalaemia, hypophosphataemia; headache, paraesthesia; worsening heart failure, QT prolongation; hypotension; myalgia.
Drug Interactions
Increased risk of severe hypocalcaemia w/ drugs reducing serum Ca. Cinacalcet (should not be given to patients receiving Parsabiv).
ATC Classification
H05BX04 - etelcalcetide ; Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis.
Parsabiv soln for inj 2.5 mg/0.5 mL
10 × 1's
Parsabiv soln for inj 5 mg/mL
10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in